AAV1-CAG-GFP/Human-SNCA-miRNA

AAV1-CAG-GFP/Human-SNCA-miRNA is a ready-to-use adeno-associated virus serotype 1 vector designed for efficient and traceable gene knockdown of human alpha-synuclein (SNCA). This vector is constructed based on the widely expressed CAG promoter, which simultaneously drives the expression of both the GFP reporter gene and a miRNA targeting human SNCA. This ensures that gene silencing activity and fluorescent labeling occur in the same transduced cells, reliably linking phenotype to transduction. The AAV1 capsid is widely used due to its strong tropism for neurons and specific peripheral tissues, good safety profile, and ability to achieve stable, long-term episomal expression with minimal genomic integration. Embedding short hairpin RNA into a microRNA scaffold utilizes endogenous miRNA processing mechanisms, potentially reducing cytotoxicity and improving specificity compared to traditional shRNA methods.

This vector is ideally suited for preclinical research into alpha-synuclein biology in Parkinson''s disease and related synucleinopathies. In cell-based systems—including human iPSC-derived neurons, primary neuronal cultures, and 3D organoids—it can controllably reduce human SNCA expression to investigate its effects on protein homeostasis, aggregation, autophagy-lysosomal pathways, mitochondrial function, synaptic transmission, and neuronal survival. In animal studies, it can support region- and cell-type-specific studies of alpha-synuclein''s role in neurodegenerative cascades, neural circuit function, axonal transport, and neuroinflammation, as well as its interactions with genetic risk factors or environmental stressors. The GFP reporter gene facilitates rapid assessment of transduction efficiency, anatomical distribution, and enrichment based on cell sorting or imaging, enabling precise structure-function analysis and longitudinal tracking.